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Edited by Lukas HuberAbstract Danggui Buxue Tang (DBT) is prepared from Radix
Astragali and Radix Angelicae Sinensis. This Chinese herbal
decoction has been shown to stimulate the proliferation of T-lym-
phocytes; however, the action mechanism of this stimulation has
not been revealed. In cultured T-lymphocytes, application of
DBT markedly induced the cell proliferation, the release of
interleukin-2, -6 and -10, as well as the phosphorylation of extra-
cellular signal-regulated kinases (ERK). The pre-treatment of
ERK inhibitor blocked the DBT-induced immune responses. In
addition, the polysaccharide-enriched fraction of DBT showed
marked responses on the cultured T-lymphocytes suggesting
the important role of DBT polysaccharide in triggering such im-
mune responses.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Among thousands of herbal formulae from traditional Chi-
nese medicine (TCM), Danggui Buxue Tang (DBT; a herbal
decoction) is a simple combination of only two herbs. DBT
was ﬁrst described in Neiwaishang Bianhuo Lun by Li Dongyu-
an in China in AD 1247. Li described the DBT formula should
include: 10 qian of Radix Astragali (RA), roots of Astragalus
membranaceus (Fisch.) Bunge or Astragalus membranaceus
(Fisch.) Bunge var. mongholicus (Bunge) P.K. Hsiao, and
two qian of Radix Angelicae Sinensis (RAS), roots of Angelica
sinensis (Oliv.) Diels. One qian equals about 3 g. The mixed
herbs were boiled in two bowls (500 ml) of water over mod-
erate heat until the ﬁnal volume was reduced by half. Tradi-
tionally, DBT has been prescribed to women in China as a
remedy for menopausal symptoms. These women are directed
to drink DBT daily to raise their Qi (vital energy) and nourish
their Blood (body circulation). RA has been proven to be an
immunostimulant, hepatoprotective, anti-diabetic, analgesic,Abbreviations: TCM, Traditional Chinese medicine; DBT, Danggui
Buxue Tang; RA, Radix Astragali; RAS, Radix Angelicae Sinensis;
ERK, extracellular signal-regulated kinase
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doi:10.1016/j.febslet.2007.09.053expectorant and sedative drug [1]. On the other hand, RAS
is used to invigorate the blood circulation in treating menstrual
disorders and to modulate the immune system [2,3]. Although
chemical and biological analyses have been performed on the
individual herbs [4,5], the rationale for having two herbs in
DBT has never been explained; this consequently hinders the
development of multi-herb decoctions as disease and disorder
remedies.
By determining the chemical and biological properties of
DBT, the optimized conditions for extraction have been
established [4,6], which, interestingly, are in accord with the
weight ratio of 5:1 for RA to RAS in the ancient preparation.
In addition, a standardized DBT was established by revealing
the amounts of RA-derived calycosin and formononetin, and
RAS-derived ferulic acid and ligustilide in the decoction [5,7].
The immuno-regulatory property (one of the Qi functions)
of DBT was determined here. Previous studies indicated that
the proliferation of T-lymphocytes could be stimulated by
the treatment of DBT; however, the molecular event responsi-
ble for this stimulation has not been determined. To reveal the
action mechanism of this ancient herbal decoction, we treated
cultured T-lymphocytes with DBT and, subsequently,
analyzed the releases of ten cytokines including interleukin
(IL)-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, granulocyte–mac-
rophage colony stimulating factor (GM-CSF), interferon-c
(IFN-c), tumor necrotic factor-a (TNF-a) and the phosphory-
lation of extracellular signal-regulated kinases (ERK)1/2.
In addition, the role of DBT polysaccharide and its signal-
ing pathway for the DBT-induced cytokine release was
elucidated.2. Materials and methods
2.1. Preparation and standardization of DBT
Three-year-old A. membranaceus var. mongholicus roots from
Shanxi Province [8] and two-year-old A. sinensis roots from Minxian
in Gansu Province [3] were collected in 2002. In preparing DBT, exact
amounts of RAS and RA were weighed according to a ratio of 5:1 and
then mixed well in a vortex. The mixture was boiled in 8 vol of water
(v/w) for 2 h and extracted twice; this extraction followed the ancient
recipe that had been shown to have the best extracting condition
[4,6]. Separate samples of RAS and RA were extracted by the same
method. DBT polysaccharides were separated into polysaccharide-en-
riched fraction and polysaccharide-depleted fraction by precipitating
the DBT extract with 70% ethanol. The two fractions were separated
after centrifugation at 4000 · g for 20 min. The polysaccharide-en-
riched fraction accounts for 18% of the total dried weight. All the
fractions were dried by lyophilization and stored at 80 C.blished by Elsevier B.V. All rights reserved.
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tents of ferulic acid, calycosin, formononetin and ligustilide (z-iso-
form). AR- and HPLC-grade reagents were from Merck (Darmstadt,
Germany). A Waters (Milford, MA) HPLC system consisting of a
600 pump, a 717 auto-sampler and a UV/VIS Photodiode Array
2996 Detector was used for all analyses. Chromatographic separations
were carried out on a DELTA-PAK C18 column (particle size 4.6 lm,
3.9 mm · 150 mm) with acetonitrile (as Solvent A) and: 0.01% phos-
phoric acid (as Solvent B) in the mobile phase at a ﬂow rate of
1.0 ml/min at room temperature, as described previously [5–7].
2.2. T-lymphocyte culture and proliferation assay
Human T-lymphocytes were isolated from freshly collected blood of
healthy donors by Ficoll-Hypaque [9]. The puriﬁed T-lymphocytes
were washed twice with RPMI-1640 medium (Invitrogen, Carlsbad,
CA) and seeded at a density of 1 · 105 cells/well in a 96-well culture
plate. Six densities of T-lymphocytes (1 · 104–1 · 106 cells/well)
were seeded for making the standard curve of XTT assay. Cultured
T-lymphocytes were treated with DBT, RA, RAS, the mixture of
RA and RAS, or phytohaemagglutinin (PHA) for 3 days. Then, 1 ml
of XTT solution (1 mg/ml; Sigma, St. Louis, MO) was mixed with
5 ll of phenazine methosulfate at 5 mM. Twenty-ﬁve microliters of
mixed XTT solution was added to each well, and the cultures were
incubated for 4 h in a water-saturated atmosphere of 95% air and
5% CO2. Absorbance at 450 nm was measured. The cell number was
determined from the standard curve. In the blocking analyses, MEK
inhibitor U0126 (20 lM; Sigma), dissolved in dimethyl sulfoxide
(DMSO), was applied 3 h before the application of other drugs. 12-
O-Tetradecanoylphorbol 13-acetate (TPA; Sigma) at 0.1 lM was used
as an ERK activator.
2.3. Cytokine antibody array and ELISA
The secretion of diﬀerent cytokines from cultured T-lymphocytes
was measured by using Quantibody Human Th1/Th2 Array from
Ray Biotech (Norcross, GA). In brief, antibodies against diﬀerent
cytokine (IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, GM-CSF, IFN-
c and TNF-a) were spotted onto the cytokine array by manufacturer.
T-lymphocytes were treated with DBT for 3 days. The amount of se-
creted cytokines was measured by adding 100 ll of conditioned med-
ium onto the array for 2 h. Then, biotin-conjugated primary
antibodies were added for 1 h. After washing, Alexa 555-conjugated
streptavidin was added for 1 h. The chip was scanned by GenePix
Professional 4200A (Synnyvale, CA) at excitation 555 nm and emis-
sion 565 nm. The image was analyzed by GenePix Pro 5.0 software
program, and the amount of cytokine was quantiﬁed according to
the standard curve calibrated from the same array. The secreted IL-
2, IL-6 and IL-10 from T-lymphocytes were further measured by using
eBioscience ELISA kit (San Diego, CA). T-lymphocytes were treated
with DBT for 3 days. One hundred microliters of conditioned medium
in each well was collected, and the amount of IL-2, IL-6 and IL-10
were measured by following the protocol provided from the ELISA
kit’s manufacturer. Finally, the plates were measured at absorbance
450 nm and calibrated.Pr
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Fig. 1. Eﬀects of extracts from RA, RAS and DBT in cultured
T-lymphocytes. DBT, or RA, or RAS, or RA + RAS at diﬀerent
amounts were applied onto cultured T-lymphocytes for 3 days. PHA
(10 lg/ml) was used as a positive control. Values of cell proliferation
(by XTT assay) are expressed in percentage of increase as compared to
control cultures (without herbal extract). Values are in means ±
S.E.M., where n = 5, each with triplicate samples.2.4. Determination of ERK1/2 phosphorylation
Cultured T-lymphocytes were treated with DBT for 0, 10, 20, 30, 45,
60 min, respectively. To investigate the eﬀect of inhibitor, the cultures
were serum starved with or without the inhibitor for 3 h before the
drug applications. After the drug treatments, the cultures were col-
lected immediately in lysis buﬀer (125 mM Tris–HCl, 2% SDS, 10%
glycerol, 200 mM 2-mercaptoethanol, pH 6.8), and the proteins were
subjected to SDS–PAGE analysis. Phosphorylated ERK1/2 were rec-
ognized by anti-phospho-ERK1/2 and anti-total ERK1/2 antibodies
(1:5000; Cell Signaling, Danvers, MA) at 4 C for 12 h, and horserad-
ish peroxidase (HRP)-conjugated anti-rabbit secondary antibody
(1:5000; Invitrogen) for 1 h at room temperature. The immuno-com-
plexes were visualized by the enhanced chemiluminescence (ECL)
method (GE Healthcare; Piscataway, NJ). The band intensities, recog-
nized by the antibodies in the ECL ﬁlm, in control and agonist-stimu-
lated samples were run on the same gel and under strictly standardized
ECL conditions. The bands were compared on an image analyzer,
using in each case a calibration plot constructed from a parallel gel
with serial dilution of one of those samples: this was to ensure the
sub-saturation of the gel exposure.2.5. Other assays
The protein concentrations were measured routinely by Bradford’s
method with a kit from Bio-Rad Laboratories (Hercules, CA). Statis-
tical tests were made by the PRIMER program, version 1 (Primer of
Biostatistics): diﬀerences from basal or control values (as shown in
the plots) were classed as signiﬁcant (*) where P < 0.05, (**) where
P < 0.01 and highly signiﬁcant (***) where P < 0.001 by Student’s
t-test.3. Results
3.1. Standardization of DBT
By discovering the amounts of two chemical markers in RA
(calycosin and formononetin) and two others in RAS (ferulic
acid and ligustilide), we were able to standardize the optimal
DBT. The standardized DBT should contain 0.186 mg calyco-
sin, 0.155 mg formononetin, 0.351 mg ferulic acid and
0.204 mg ligustilide per 1 g dried weight of DBT, which was
in line with our previous calibration [5,7]. From the extraction
eﬃciency calculations, we found that the yield of DBT in this
weight ratio was 32 ± 3% (n = 5). These parameters established
the chemical standards and the optimal DBT mixture for the
remaining biochemical experiments.
3.2. DBT induces T-lymphocyte proliferation
In order to reveal the possible immune-regulatory functions
of DBT, water extracts of DBT, RA, RAS, and RA + RAS
(boiled separately and then mixed together in 5:1 ratio) were
applied onto the cultured human T-lymphocytes, and the cell
proliferation was determined. All groups showed signiﬁcant
stimulatory eﬀect on T-lymphocyte proliferation (Fig. 1).
The eﬀects of diﬀerent herbal extracts showed a good dose-
dependent response. At the dosage of 0.1 mg/ml, DBT showed
the sub-maximal eﬀect, which was signiﬁcantly higher than the
other groups. Higher amount of the extracts did not show sig-
niﬁcant increase in the cell proliferation, suggesting a satura-
tion eﬀect. The addition of RA + RAS (boiled separately)
showed a much lower activation eﬀect on the T-lymphocyte
proliferation.
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Cultured T-lymphocytes were treated for 3 days with ex-
tracts derived from DBT, RA, RAS, or RA + RAS. The re-
lease of cytokines (IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13,
GM-CSF, IFN-c and TNF-a) from the drug-treated T-lym-
phocytes was determined by cytokine antibody array. By com-
paring to the control cultures, the releases of IL-2, IL-6, IL-8
and IL-10 were markedly induced by DBT (Fig. 2A).
Amongst the four cytokines, IL-2, IL-6 and IL-10 showed
the speciﬁcity for DBT, i.e. not induced by RA, RAS or
RA + RAS, and thus they were selected for further analysis.
The treatment of DBT caused an increase in the release of
IL-2 to 3-fold, IL-6 to 120-fold and IL-10 to 20-fold.
Interestingly, the treatment of RA, RAS or a simple mixture
of RA and RAS did not change the release of the cytokines
suggested that boiling of two herbs together is essential. The
levels of IL-4, IL-5, IL-13, GM-CSF, IFN-c and TNF-a were
not aﬀected by the treatment of DBT, RA, RAS, and
RA + RAS.
The releases of IL-2, IL-6 and IL-10 were quantiﬁed by an
ELISA assay. Fig. 2B and C shows a dose–response curve
for the releases of cytokines after DBT treatment. The re-
sponses of the three cytokines were rather similar, i.e.
0.1 mg/ml of DBT in all cases induced the release to a maxi-A
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Fig. 2. Screening of cytokine release in DBT-treated T-lymphocytes by cytoki
0.1 mg/ml) were applied onto cultured T-lymphocytes for 3 days. (A) The con
amount of diﬀerent cytokines. (B, C) The amounts of cytokines (IL-2, IL-6
ELISA. Values are expressed as the ratio to basal or control reading where t
*P < 0.05 and ***P < 0.001 as compared to other groups.mum; the maximal induction for IL-2 was at 4-fold, IL-6
at 20-fold, and IL-10 at 8-fold. By comparing the results
from the cytokine array analysis, the results from ELISA assay
revealed a lower value, which could be accounted by the sensi-
tivity of the two diﬀerent assay systems.
3.4. DBT induces ERK phosphorylation
Activation of ERK, a member of mitogen-activated protein
(MAP) kinases that acts as a key signal for T-lymphocyte pro-
liferation, was determined in DBT-treated cells. By using anti-
bodies speciﬁc for phosphorylated ERK and total ERK, the
phosphorylations of the ERK1 (44 kDa) and ERK2
(42 kDa) in cultured T-lymphocytes were revealed: both of
the phosphorylations were increased by application of DBT
(Fig. 3A and B). The maximal induction of 10-fold on
ERK phosphorylation was revealed after 30 min of DBT
application. The ERK activation was transient, which fully re-
turned to a low level after 60 min of the treatment. The appli-
cation of TPA, served as a control, signiﬁcantly induced
ERK1/2 phosphorylation at a more sustained manner, which
is more robust than that of DBT. The DBT-induced ERK
phosphorylation at 30 min was fully blocked by pre-treating
the cultures with U0126 (20 lM; a MEK inhibitor) (Fig. 3C
and D).A
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for 30 min. DMSO (a solvent for U0126 at 0.1%) served as a control. (D) The quantitation of phosphorylation from the blots in (C) by calibrating the
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Fig. 4. The DBT-induced immuno-modulating eﬀects are mediated by
ERK1/2. T-lymphocytes were pre-treated with buﬀer (0.1% DMSO),
or 20 lM U0126, for 3 h before the addition of DBT (0.1 mg/ml) for 3
days. The proliferation of T-lymphocyte was assayed by XTT, and the
amounts of cytokines were determined by ELISA assay as in Fig. 3.
Values are expressed as the ratio to basal reading where the untreated
culture equals to 1, and in means ± S.E.M., where n = 4. **P < 0.01
and ***P < 0.001 as compared to the buﬀer control.
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of DBT were related to the ERK1/2 phosphorylation, the re-
lease of cytokines in the DBT-treated T-lymphocytes in the
present of U0126 was tested. The DBT-induced T-lymphocyte
proliferation was fully blocked by U0126 (Fig. 4). In parallel,
the releases of IL-2, IL-6 and IL-10, induced by DBT, were
blocked by the pre-treatment of U0126 (Fig. 4). These results
strongly showed that the pre-treatment of MEK inhibitor
could fully abolish the immune-regulatory eﬀects of DBT on
T-lymphocytes, and which suggested the crucial role of ERK
in mediating the immune responses of DBT.
3.5. The polysaccharide of DBT is an immune activator
In order to identify the active component within DBT in
triggering the aforementioned immune activations, two frac-
tions: polysaccharide-enriched (18% of the dried weight)
and polysaccharide-depleted (82% of the dried weight) frac-
tions were obtained. The polysaccharide-enriched fraction,
when applied onto the cultured T-lymphocytes, showed a
marked increase in its immune activation eﬀect. At 50 lg/ml
CA B
D
A
m
ou
nt
 o
f I
L-
6 
(x 
Ba
sa
l)
0
5
10
15
20
25
30
Extract (μg/ml)
10050 30075250
PS-enriched
PS-depleted
A
m
ou
nt
 o
f I
L-
2 
(x 
Ba
sa
l)
Extract (μg/ml)
10050 30075250
0
2
4
6
8
PS-enriched
PS-depleted
Pr
ol
ife
ra
tio
n 
(%
 of
 in
cre
as
e)
20
40
60
80
100
0
0 50 100 200 400150
Extract (μg/ml)
PS-enriched
PS-depleted
A
m
ou
nt
 o
f I
L-
10
 (x
 B
as
al)
Extract (μg/ml)
10050 30075250
0
2
4
6
8
10 PS-enriched
PS-depleted
Fig. 5. DBT polysaccharide induces the T-lymphocyte proliferation and cytokine release. Cultured T-lymphocytes were treated with polysaccharide-
enriched (PS-enriched) and polysaccharide-depleted (PS-depleted) fractions for 3 days. (A) Values of cell proliferation (by XTT assay) are expressed
in percentage of increase as compared to control cultures (without herbal extract). (B–D) The amounts of cytokines (IL-2, IL-6 and IL-10) in the
conditioned medium (0.1 ml) were determined by ELISA. Values are expressed as the ratio to basal or control reading where the untreated culture
equals to 1. Data were expressed in means ± S.E.M., where n = 4.
Q.T. Gao et al. / FEBS Letters 581 (2007) 5087–5093 5091of polysaccharide-enriched fraction, the stimulation of cell
proliferation was increased by over 50% that was 5-fold high-
er than that of polysaccharide-depleted fraction (Fig. 5A). In
parallel, the polysaccharides-enriched fraction showed a higher
activation eﬀect in stimulating the release of cytokines. At
50 lg/ml of polysaccharide-enriched fraction, the releases of
IL-2, IL-6 and IL-10 were increased by 4-fold, 20-fold
and 6-fold, respectively (Fig. 5B–D). In comparison, the
polysaccharides-depleted fraction could only slightly induce
the cytokine release.
The phosphorylations of the ERK1 (44 kDa) and ERK2
(42 kDa) in cultured T-lymphocytes were increased by appli-
cation of the polysaccharides-enriched fraction (Fig. 6A and
B). Similar to the eﬀect of DBT, the maximal induction of
12-fold on ERK phosphorylation was revealed after 30 min
of the polysaccharides-enriched fraction of DBT application.
The eﬀects of DBT polysaccharides were also fully blocked
by pre-treating the cultures with U0126 (Fig. 6C and D). In
contrast, the polysaccharides-depleted fraction prepared from
DBT did not show activation in the ERK phosphorylation
(Fig. 6A and B). The signaling pathway of DBT is similar to
that of its polysaccharide, and which indicates the role of poly-
saccharide in triggering the immune responses.
4. Discussion
DBT, an ancient Chinese herbal decoction having a combi-
nation of RA and RAS in a weight ratio of 5:1, possesses muchbetter eﬀect in stimulating cultured T-lymphocytes as com-
pared to that of the extracts derived from RA, or RAS, or
RA + RAS (boiled separately and then mixed together in 5:1
ratio). In parallel to this eﬀect, cytokine array analysis revealed
a speciﬁc set of cytokines including IL-2, IL-6 and IL-10 being
stimulated to release from the cultured T-lymphocytes by
DBT; the cytokine release was not triggered by RA alone, or
RAS alone, or RA + RAS. In addition, the insuﬃcient stimu-
lating eﬀect of RA + RAS in cultured T-lymphocytes suggests
that boiling of the two herbs together is essential; this method
of DBT preparation, indeed, has long been recommended by
TCM practitioners. Besides the eﬀect in T-lymphocytes, the
role of the correct weight ratio of RA to RAS in making the
formulation of DBT has also been demonstrated in cultured
breast cancer [7], macrophage [5] and osteoblast [4].
Why does DBT need the boiling of two herbs together and at
a ratio of 5:1? The author of DBT, Li Dongyuan, one of the
four well-known TCM practitioners in Jin and Yuan Dynasty
(the period from 1115 to 1368 A.D.), wrote down the formula-
tion, probably based on accumulated experience in clinical
application. The theoretical framework of Chinese medicine
is the ﬁve elements: Metal, Wood, Water, Fire and Earth.
The ﬁve elements represent diﬀerent organs of our body and
work harmoniously to keep the body balance [10]. Li was a
great believer of ‘‘School of Reinforce Earth’’ that is corre-
sponding to the organ of Spleen and the function of Qi; both
of them are referring to the immune functions. According to
Yijing, a book of ancient Chinese philosophy, Earth represents
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were combined at a ratio of 5:1, DBT should have the best ef-
fect in reinforcing Qi and nourishing Blood for the menopausal
symptoms.
Two possible hypotheses could explain the unique biological
functions of DBT. First, DBT might contain new chemicals or
larger amount of active constituents than those in the extracts
of RA or RAS alone. The boiling of RA and RAS together
might enhance the solubility of new chemicals, and the new
chemicals are only soluble in DBT. These additional chemicals
could be responsible for the DBT-speciﬁc eﬀects. On the other
hand, the optimized ratio of the two herbs in yielding more ac-
tive ingredients can be another good explanation for the DBT-
speciﬁc eﬀects. The present results suggested that the polysac-
charide fraction should contain one of the active ingredients of
DBT. In line with that, chemical analyses showed that the con-
tent of polysaccharides in DBT was much higher than just add-
ing RA and RAS together [4]. In addition, higher amounts of
RA-derived calycosin, formononetin and RAS-derived ferulic
acid were also found in DBT decoction [4]. Second, there could
be a synergistic eﬀect of diﬀerent components in DBT; this syn-
ergistic eﬀect is not present in the extracts of the single herbs.
This hypothesis is being supported by the fact that the polysac-charide-enriched fraction could not fully account the activity
of DBT, in particular the enrichment of the activity within
the polysaccharide-enriched fraction could not be revealed
here. Currently, we still do not have a direct evidence to ex-
plain why DBT required the two diﬀerent herbs.
DBT possesses signiﬁcant eﬀect on T-lymphocyte prolifera-
tion, and this eﬀect, possibility, could be a result of the in-
creased releases of IL-2, IL-6 and IL-10. This notion is
strongly supported by the eﬀect of MEK inhibitor that blocked
the cytokine release as well as the proliferation of T-lympho-
cyte. Cytokines are a set of soluble proteins that play a key role
in immuno-regulation in both innate and adaptive immune re-
sponses [11,12]. Among the DBT-speciﬁc activated cytokines,
IL-2 is an important growth factor for T-lymphocyte, which
could amplify lymphocyte responses in vivo [13]. The up regu-
lation of IL-2 by DBT might be one of the important mecha-
nisms for DBT’s eﬀect on T-lymphocyte proliferation. IL-10 is
a growth factor for B lymphocytes and is responsible for their
diﬀerentiation; it can induce immunoglobulin secretion by B-
lymphocyte [14,15]. Besides, IL-10 is a potent stimulator of
NK cells, a function involved in inﬂammation that might con-
tribute to the clearance of the pathogen and facilitate antigen
acquisition from dead cells [16]. IL-6 is a multifunctional cyto-
Q.T. Gao et al. / FEBS Letters 581 (2007) 5087–5093 5093kine that plays important roles not only in the immune system,
but also in hematopoiesis, and acute phase reactions [17]. In
addition to the aforementioned in vitro properties of DBT,
the eﬀects of DBT has also been tested and proven in previous
animal studies. In DBT-administered mice, the formulation
with RA and RAS at 5:1 ratio was the most eﬀective decoction
in triggering the immune responses; these responses included
the amount of lymphocytes, macrophages and the release of
IL-2 [18,19].
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